275 related articles for article (PubMed ID: 19650707)
1. Cyclosporine A eye drops inhibit the early-phase reaction in a type-I allergic conjunctivitis model in mice.
Shii D; Oda T; Shinomiya K; Katsuta O; Nakamura M
J Ocul Pharmacol Ther; 2009 Aug; 25(4):321-8. PubMed ID: 19650707
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporin A eye drops inhibit fibrosis and inflammatory cell infiltration in murine type I allergic conjunctivitis without affecting the early-phase reaction.
Shii D; Nakagawa S; Shinomiya K; Yoshimi M; Katsuta O; Oda T; Nakamura M
Curr Eye Res; 2009 Jun; 34(6):426-37. PubMed ID: 19899977
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions.
Fukushima A; Yamaguchi T; Ishida W; Fukata K; Liu FT; Ueno H
Clin Exp Ophthalmol; 2006; 34(4):347-53. PubMed ID: 16764655
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of cyclosporine a eye drops on symptoms in late phase and delayed-type reactions in allergic conjunctivitis models.
Shii D; Nakagawa S; Yoshimi M; Katsuta O; Oda T; Nakamura M
Biol Pharm Bull; 2010; 33(8):1314-8. PubMed ID: 20686224
[TBL] [Abstract][Full Text] [Related]
5. The anti-allergic effects of a cromolyn sodium-chlorpheniramine combination compared to ketotifen in the conjunctival allergen challenge model.
Leonardi A; Busca F; Tavolato M; Secchi AG
Eur J Ophthalmol; 2003 Mar; 13(2):128-33. PubMed ID: 12696630
[TBL] [Abstract][Full Text] [Related]
6. DP2 (CRTh2) antagonism reduces ocular inflammation induced by allergen challenge and respiratory syncytial virus.
Stebbins KJ; Broadhead AR; Musiyenko A; Barik S; Scott JM; Truong YP; Stearns BA; Hutchinson JH; Prasit P; Evans JF; Lorrain DS
Int Arch Allergy Immunol; 2012; 157(3):259-68. PubMed ID: 22042170
[TBL] [Abstract][Full Text] [Related]
7. Topical cyclosporine inhibits mast cell-mediated conjunctivitis.
Whitcup SM; Chan CC; Luyo DA; Bo P; Li Q
Invest Ophthalmol Vis Sci; 1996 Dec; 37(13):2686-93. PubMed ID: 8977483
[TBL] [Abstract][Full Text] [Related]
8. Treatment with galectin-1 eye drops regulates mast cell degranulation and attenuates the severity of conjunctivitis.
Mello-Bosnic C; Gimenes AD; Oliani SM; Gil CD
Eur J Pharmacol; 2018 Aug; 833():124-130. PubMed ID: 29859836
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional analyses before and after suppression of immediate hypersensitivity reactions by CCR3 blockade in eyes with experimental allergic conjunctivitis.
Komatsu N; Miyazaki D; Tominaga T; Kuo CH; Namba S; Takeda S; Higashi H; Inoue Y
Invest Ophthalmol Vis Sci; 2008 Dec; 49(12):5307-13. PubMed ID: 18658092
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.
Abelson MB; Ferzola NJ; McWhirter CL; Crampton HJ
Pediatr Allergy Immunol; 2004 Dec; 15(6):551-7. PubMed ID: 15610370
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM; Tekelioglu Y; Turk A; Akyol N
Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
[TBL] [Abstract][Full Text] [Related]
12. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
[TBL] [Abstract][Full Text] [Related]
13. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
14. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
[TBL] [Abstract][Full Text] [Related]
15. [Ketotifen fumarate (Zaditen) eye drops in the treatment of seasonal allergic conjunctivitis].
Haicl P; Cerná H
Cesk Slov Oftalmol; 2004 Sep; 60(5):362-7. PubMed ID: 15566225
[TBL] [Abstract][Full Text] [Related]
16. Involvement of chymase in allergic conjunctivitis of guinea pigs.
Nabe T; Kijitani Y; Kitagawa Y; Sakano E; Ueno T; Fujii M; Nakao S; Sakai M; Takai S
Exp Eye Res; 2013 Aug; 113():74-9. PubMed ID: 23726880
[TBL] [Abstract][Full Text] [Related]
17. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
Galatowicz G; Ajayi Y; Stern ME; Calder VL
Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
[TBL] [Abstract][Full Text] [Related]
18. Dietary cholesterol is essential to mast cell activation and associated obesity and diabetes in mice.
Zhang X; Huang Q; Wang X; Deng Z; Li J; Yan X; Jauhiainen M; Metso J; Libby P; Liu J; Shi GP
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1690-1700. PubMed ID: 30978390
[TBL] [Abstract][Full Text] [Related]
19. Treatment with FTY720 during the induction or effector phase suppresses the development of experimental allergic conjunctivitis in mice.
Sumi T; Fukushima A; Nishino K; Fukuda K; Kumagai N; Nishida T; Ueno H
Cell Biol Int; 2009 Apr; 33(4):534-41. PubMed ID: 19230848
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of eye allergies].
Kari O; Saari KM
Duodecim; 2012; 128(3):291-7. PubMed ID: 22428383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
